tradingkey.logo
tradingkey.logo
Suchen

Cytek Biosciences Inc

CTKB
Zur Watchlist hinzufügen
4.590USD
+0.010+0.22%
Handelsschluss 07/02, 13:00ETKurse um 15 Minuten verzögert
590.05MMarktkapitalisierung
VerlustKGV TTM

mehr Informationen über Cytek Biosciences Inc Unternehmen

Cytek Biosciences, Inc. is a cell analysis solutions company. The Company is advancing the cell analysis tools by delivering high-resolution, high-content, and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling (FSP) technology. Its platform includes its core FSP instruments, the Cytek Aurora and Northern Lights systems and the Cytek Aurora CS cell sorter; the Cytek Orion reagent cocktail preparation system; the Enhanced Small Particle (ESP) detection technology; the flow cytometer and imaging products under the Amnis and Guava brands, and reagents, software and service to provide a comprehensive and integrated suite of solutions for its customers. Its Cytek Aurora and Northern Lights systems are used in the study of infectious diseases, immunology, immunotherapy, immuno-oncology, oncology, and drug discovery. The Cytek Orion reagent cocktail preparation system enables researchers to fully automate the preparation of antibody cocktails for flow cytometry.

Cytek Biosciences Inc Informationen

BörsenkürzelCTKB
Name des UnternehmensCytek Biosciences Inc
IPO-datumJul 23, 2021
CEOJiang (Wenbin)
Anzahl der mitarbeiter648
WertpapierartOrdinary Share
GeschäftsjahresendeJul 23
Addresse47215 Lakeview Boulevard
StadtFREMONT
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl94538
Telefon18779229835
Websitehttps://cytekbio.com
BörsenkürzelCTKB
IPO-datumJul 23, 2021
CEOJiang (Wenbin)

Führungskräfte von Cytek Biosciences Inc

Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Wenbin Jiang, Ph.D.
Dr. Wenbin Jiang, Ph.D.
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Chairman of the Board, President, Chief Executive Officer, Co-Founder
5.48M
+1.00%
Dr. Ming Yan, Ph.D.
Dr. Ming Yan, Ph.D.
Co-Founder, Chief Technology Officer, Director
Co-Founder, Chief Technology Officer, Director
4.80M
-2.83%
Ms. Valerie Barnett, J.D.
Ms. Valerie Barnett, J.D.
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
150.01K
+10.38%
Mr. Michael Holder
Mr. Michael Holder
Independent Director
Independent Director
60.69K
+72.45%
Dr. Vera Imper, Ph.D.
Dr. Vera Imper, Ph.D.
Independent Director
Independent Director
59.68K
+73.68%
Ms. Deborah J. Neff
Ms. Deborah J. Neff
Lead Independent Director
Lead Independent Director
59.68K
+73.68%
Mr. William (Bill) Mccombe
Mr. William (Bill) Mccombe
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Philippe Busque, Ph.D.
Dr. Philippe Busque, Ph.D.
Senior Vice President, Global Sales and Services
Senior Vice President, Global Sales and Services
--
--
Mr. Jack T. Ball, Jr.
Mr. Jack T. Ball, Jr.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Wenbin Jiang, Ph.D.
Dr. Wenbin Jiang, Ph.D.
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Chairman of the Board, President, Chief Executive Officer, Co-Founder
5.48M
+1.00%
Dr. Ming Yan, Ph.D.
Dr. Ming Yan, Ph.D.
Co-Founder, Chief Technology Officer, Director
Co-Founder, Chief Technology Officer, Director
4.80M
-2.83%
Ms. Valerie Barnett, J.D.
Ms. Valerie Barnett, J.D.
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
150.01K
+10.38%
Mr. Michael Holder
Mr. Michael Holder
Independent Director
Independent Director
60.69K
+72.45%
Dr. Vera Imper, Ph.D.
Dr. Vera Imper, Ph.D.
Independent Director
Independent Director
59.68K
+73.68%
Ms. Deborah J. Neff
Ms. Deborah J. Neff
Lead Independent Director
Lead Independent Director
59.68K
+73.68%

Häufig gestellte Fragen

Wer sind die fünf größten Anteilseigner von Cytek Biosciences Inc?

Die fünf größten Anteilseigner von Cytek Biosciences Inc sind: Dr. Wenbin Jiang, Ph.D.

Wie viele Institutionen halten Anteile an Cytek Biosciences Inc (CTKB)?

Mit Stand vom 2026Q1 halten 335 Institutionen Anteile an Cytek Biosciences Inc, mit einem Gesamtmarktwert von etwa 84.13M, was 65.16% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -7060937.00 gestiegen.

Was ist die größte Einnahmequelle von Cytek Biosciences Inc?

Am 2026Q1 erzielte das Geschäft mit Biotechnology, pharmaceutical, distributor and CRO für Cytek Biosciences Inc den höchsten Umsatz in Höhe von 116.73M, was 57.93% des Gesamtumsatzes entspricht.